RFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICSRFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICS
Home/Compounds/Retatrutide
GLP-1 agonistRx required

Retatrutide

Also known as: LY3437943 · Triple G

Triple agonist (GIP/GLP-1/glucagon) in Phase 3 trials showing up to 24% weight loss.

B
Grade B
Human observational studies
Human studies25
PubMed citations30
Typical dose500 mcg – 12 mg
Routesubcutaneous
Regulatory (US)Rx required
Last verifiedyesterday
TL;DR · 30-second summary
  • Up to 24.2% weight loss at 12mg dose in Phase 2
  • Superior to tirzepatide in early comparisons
  • Significant improvements in metabolic parameters
  • Phase 3 trials ongoing (2024-2025)

Mechanism of action

First triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Glucagon component may enhance fat oxidation and energy expenditure.

Evidence summary

25
Human studies
30
PubMed citations
0
Clinical trials
B
Evidence grade

Phase 2 trials showed unprecedented 24% weight loss at highest doses. Currently in Phase 3 trials for obesity and diabetes.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
500 mcg – 12 mg

Investigational. Phase 2 used 1-12mg weekly with dose escalation.

Administration routes
subcutaneous

Side effects & safety

Reported side effects
NauseaDiarrheaVomitingConstipationSimilar GI profile to GLP-1s
Contraindications
  • Not yet established - investigational

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Investigational - Phase 3 clinical trials

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/17/2026

Citations

PMID 41054801Son JW, le Roux CW et al. · Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews (2026)HumanPMID 41785010Panou T, Gouveri E et al. · Retatrutide in type 2 diabetes mellitus and obesity: an overview.Expert review of clinical pharmacology (2026)HumanPMID 40094000Marathe SJ, Grey EW et al. · Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.npj metabolic health and disease (2026)PMID 40022548Madsbad S, Holst JJ · The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.Expert opinion on investigational drugs (2025)HumanPMID 41090431Giblin K, Kaplan LM et al. · Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.Diabetes, obesity & metabolism (2025)HumanPMID 38302593Melson E, Ashraf U et al. · What is the pipeline for future medications for obesity?International journal of obesity (2005) (2025)HumanPMID 39761578Moiz A, Filion KB et al. · Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.Annals of internal medicine (2025)HumanPMID 39952695Kokkorakis M, Chakhtoura M et al. · Emerging pharmacotherapies for obesity: A systematic review.Pharmacological reviews (2025)HumanPMID 40563436Katsi V, Koutsopoulos G et al. · Retatrutide-A Game Changer in Obesity Pharmacotherapy.Biomolecules (2025)HumanPMID 40604322Caruso I, Cignarelli A et al. · Incretin-based therapies for the treatment of obesity-related diseases.npj metabolic health and disease (2025)PMID 40865172Rubio-Herrera MA, Mera-Carreiro S · Weight management treatment in obesity.Medicina clinica (2025)HumanPMID 40699363Windram M, Lovelock DF et al. · Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.Psychopharmacology (2025)HumanPMID 40916752Kanu C, Boye KS et al. · Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes, obesity & metabolism (2025)HumanPMID 38858523Sanyal AJ, Kaplan LM et al. · Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine (2024)HumanPMID 39096466Himmerich H, Bentley J et al. · Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.CNS drugs (2024)HumanPMID 38843460Drucker DJ · Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.Diabetes care (2024)HumanPMID 39481534Stefanakis K, Kokkorakis M et al. · The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.Metabolism: clinical and experimental (2024)HumanPMID 38681750Ciardullo S, Muraca E et al. · Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.Gastroenterology report (2024)HumanPMID 38687506Locatelli JC, Costa JG et al. · Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?Diabetes care (2024)HumanPMID 38183334Chong K, Chang JK et al. · Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.The Kaohsiung journal of medical sciences (2024)Human

Showing 20 of 30 papers. View all on PubMed →